A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time

British Journal of Clinical Pharmacology

Volumn 78, Issue 3, 2014, Pages 599-609

  Chin, Paul K L ^a   Wright, Daniel F B ^b   Patterson, David M ^c   Doogue, Matthew P ^a   Begg, Evan J ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c CANTERBURY HEALTH LABORATORIES   (New Zealand)

Author keywords

atrial fibrillation; blood coagulation; dabigatran; dosing; monitoring

Indexed keywords

DABIGATRAN ETEXILATE; BENZIMIDAZOLE DERIVATIVE; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; PYRIDINE DERIVATIVE;

BLEEDING; BLOOD CLOTTING; DOSE RESPONSE; DRUG BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HUMAN; PRIORITY JOURNAL; REVIEW; SCREENING; SIMULATION; THROMBIN TIME; THROMBOEMBOLISM; ATRIAL FIBRILLATION; CHEMICALLY INDUCED; DRUG MONITORING; HEMORRHAGE; PROCEDURES;

ATRIAL FIBRILLATION; BENZIMIDAZOLES; DABIGATRAN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FACTOR XA INHIBITORS; HEMORRHAGE; HUMANS; PYRIDINES; THROMBIN TIME; THROMBOEMBOLISM;

EID: 84904368894     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12364     Document Type: Review

References (72)

1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L,. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
2. Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA, Brueckmann M, Pogue J, Alings M, Amerena JV, Avezum A, Baumgartner I, Budaj AJ, Chen JH, Dans AL, Darius H, Di Pasquale G, Ferreira J, Flaker GC, Flather MD, Franzosi MG, Golitsyn SP, Halon DA, Heidbuchel H, Hohnloser SH, Huber K, Jansky P, Kamensky G, Keltai M, Kim SS, Lau CP, Le Heuzey JY, Lewis BS, Liu L, Nanas J, Omar R, Pais P, Pedersen KE, Piegas LS, Raev D, Smith PJ, Talajic M, Tan RS, Tanomsup S, Toivonen L, Vinereanu D, Xavier D, Zhu J, Wang SQ, Duffy CO, Themeles E, Yusuf S,. The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study. Circulation 2013; 128: 237-243.
3. Metcalfe S, Moodie P,. National prescribing data for dabigatran. N Z Med J 2012; 125: 97-105.
4. Southworth MR, Reichman ME, Unger EF,. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013; 368: 1272-1274.
5. Sorensen R, Gislason G, Torp-Pedersen C, Olesen JB, Fosbol EL, Hvidtfeldt MW, Karasoy D, Lamberts M, Charlot M, Kober L, Weeke P, Lip GY, Hansen ML,. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open 2013; 3: e002758.
6. Xu Y, Holbrook AM, Simpson CS, Dowlatshahi D, Johnson AP,. Prescribing patters of novel oral anticoagulants following regulatory approval for atrial fibrillation in Ontario, Canada: a population-based descriptive analysis. Can Med Assoc J Open 2013; 1: E115-119.
7. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A,. Dabigatran etexilate- A novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
8. Gulseth MP, Wittkowsky AK, Fanikos J, Spinler SA, Dager WE, Nutescu EA,. Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness. Pharmacotherapy 2011; 31: 1232-1249.
9. Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A,. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012; 107: 838-847.
10. Diener HC,. Pro: 'The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation'. Thromb Haemost 2013; 110: 493-495.
11. Troconiz IF, Tillmann C, Liesenfeld KH, Schafer HG, Stangier J,. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. J Clin Pharmacol 2007; 47: 371-382. (Pubitemid 46294714)
12. Duffull SB,. Is the ideal anticoagulant a myth? Expert Rev Clin Pharmacol 2012; 5: 231-236.
13. Wright DF, Al-Sallami HS, Duffull SB,. Is the dose of dabigatran really more predictable than warfarin? Br J Clin Pharmacol 2013; 76: 997-998.
14. Stangier J, Clemens A,. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009; 15 (Suppl. 1): 9S-16S.
15. van Ryn J, Goss A, Hauel N, Wienen W, Priepke H, Nar H, Clemens A,. The discovery of dabigatran etexilate. Front Pharmacol 2013; 4: 12.
16. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W,. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36: 386-399. (Pubitemid 351185753)
17. Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stahle H, Rathgen K, Svard R,. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005; 45: 555-563. (Pubitemid 40562946)
18. Stangier J, Stahle H, Rathgen K, Fuhr R,. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008; 47: 47-59. (Pubitemid 350260888)
19. Hartter S, Koenen-Bergmann M, Sharma A, Nehmiz G, Lemke U, Timmer W, Reilly PA,. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol 2012; 74: 490-500.
20. Pare G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD, Axelsson T, Haertter S, Oldgren J, Reilly P, Siegbahn A, Syvanen AC, Wadelius C, Wadelius M, Zimdahl-Gelling H, Yusuf S, Wallentin L,. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 2013; 127: 1404-1412.
21. Stangier J, Stahle H, Rathgen K, Roth W, Shakeri-Nejad K,. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol 2008; 48: 1411-1419.
22. Stangier J, Rathgen K, Stahle H, Mazur D,. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49: 259-268.
23. Ebner T, Wagner K, Wienen W,. Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos 2010; 38: 1567-1575.
24. Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, Yusuf S, Wallentin L, Haertter S, Staab A,. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 2011; 9: 2168-2175.
25. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L,. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients in the RE-LY trial. J Am Coll Cardiol 2014; 63: 321-328.
26. Kurnik D, Loebstein R, Halkin H, Gak E, Almog S,. 10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal. Pharmacogenomics 2009; 10: 1955-1965.
27. Chin PK, Wright DF, Doogue MP, Begg EJ,. Learning more from the dabigatran concentrations in RE-LY. J Am Coll Cardiol. doi: 10.1016/j.jacc.2013. 11.069.
28. Eikelboom JW, Connolly SJ, Hart RG, Wallentin L, Reilly P, Oldgren J, Yang S, Yusuf S,. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. J Am Coll Cardiol 2013; 62: 900-908.
29. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L,. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363: 1875-1876.
30. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S,. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363-2372.
31. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ,. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870. (Pubitemid 32537350)
32. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ,. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010; 137: 263-272.
33. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, Radford MJ,. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151: 713-719. (Pubitemid 43290267)
34. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY,. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100.
35. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE,. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011; 58: 395-401.
36. Lip GY,. Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why? Eur Heart J 2013; 34: 1041-1049.
37. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, Guidelines ESCCfP. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
38. Lip GY, Frison L, Halperin JL, Lane DA,. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 2010; 41: 2731-2738.
39. Lip GY, Frison L, Halperin JL, Lane DA,. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011; 57: 173-180.
40. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W,. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292-303. (Pubitemid 47283865)
41. Hartter S, Sennewald R, Schepers C, Baumann S, Fritsch H, Friedman J,. Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers. Eur J Clin Pharmacol 2013; 69: 327-339.
42. Hartter S, Sennewald R, Nehmiz G, Reilly P,. Oral bioavailability of dabigatran etexilate (Pradaxa(R)) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol 2013; 75: 1053-1062.
43. Delavenne X, Ollier E, Basset T, Bertoletti L, Accassat S, Garcin A, Laporte S, Zufferey P, Mismetti P,. A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. Br J Clin Pharmacol 2013; 76: 107-113.
44. Delavenne X, Moracchini J, Laporte S, Mismetti P, Basset T,. UPLC MS/MS assay for routine quantification of dabigatran- A direct thrombin inhibitor-in human plasma. J Pharm Biomed Anal 2012; 58: 152-156.
45. Bakshi M, Singh S,. Development of validated stability-indicating assay methods-critical review. J Pharm Biomed Anal 2002; 28: 1011-1040. (Pubitemid 34607392)
46. Lindahl TL, Baghaei F, Blixter IF, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Hillarp A, Expert Group on Coagulation of the External Quality Assurance in Laboratory Medicine in S. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011; 105: 371-378.
47. Stangier J, Wetzel K, Wienen W, Van Ryn J, Rathgen K,. Measurement of the pharmacodynamic effect of dabigatran etexilate: thrombin clotting time. Thromb Haemost 2009; 7 (Suppl. 2): 674.
48. Hawes EM, Deal AM, Funk-Adcock D, Gosselin R, Jeanneret C, Cook AM, Taylor JM, Whinna HC, Winkler AM, Moll S,. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost 2013; 11: 1493-1502.
49. Antovic JP, Skeppholm M, Eintrei J, Boija EE, Soderblom L, Norberg EM, Onelov L, Ronquist-Nii Y, Pohanka A, Beck O, Hjemdahl P, Malmstrom RE,. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol 2013; 69: 1875-1881.
50. Avecilla ST, Ferrell C, Chandler WL, Reyes M,. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. Am J Clin Pathol 2012; 137: 572-574.
51. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogne JM,. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012; 107: 985-997.
52. Stangier J, Feuring M,. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012; 23: 138-143.
53. Douxfils J, Dogne JM, Mullier F, Chatelain B, Ronquist-Nii Y, Malmstrom RE, Hjemdahl P,. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost 2013; 110: 543-549.
54. Hapgood G, Butler J, Malan E, Chunilal S, Tran H,. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. Thromb Haemost 2013; 110: 308-315.
55. Chin PK, Vella-Brincat JW, Barclay ML, Begg EJ,. Perspective on dabigatran etexilate dosing: why not follow standard pharmacological principles? Br J Clin Pharmacol 2012; 74: 734-740.
56. Chin PKL, Patterson DM, Zhang M, Jensen BP, Wright DFB, Barclay ML, Begg EJ,. Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran. Br J Clin Pharmacol 2014; 78: 630-638.
57. Love JE, Ferrell C, Chandler WL,. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost 2007; 98: 234-242.
58. Duffull SB, Wright DF, Al-Sallami HS, Zufferey PJ, Faed JM,. Dabigatran: rational dose individualisation and monitoring guidance is needed. N Z Med J 2012; 125: 148-154.
59. Gong IY, Kim RB,. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol 2013; 29: S24-33.
60. Brunetti L, Bandali F,. Dabigatran: is there a role for coagulation assays in guiding therapy? Ann Pharmacother 2013; 47: 828-840.
61. Chin PK, Vella-Brincat JW, Walker SL, Barclay ML, Begg EJ,. Dosing of dabigatran etexilate in relation to renal function and drug interactions at a tertiary hospital. Intern Med J 2013; 43: 778-783.
62. Chin PK, Barclay ML, Begg EJ,. Rifampicin and dabigatran etexilate: a place for laboratory coagulation monitoring. Br J Clin Pharmacol 2013; 75: 554-555.
63. Eriksson BI, Dahl OE, Buller HR, Hettiarachchi R, Rosencher N, Bravo ML, Ahnfelt L, Piovella F, Stangier J, Kalebo P, Reilly P,. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 3: 103-111. (Pubitemid 41647122)
64. Holford NH,. Target concentration intervention: beyond Y2K. Br J Clin Pharmacol 2001; 52 (Suppl. 1): 55S-59. (Pubitemid 32823032)
65. FDA. Briefing information for the September 20, 2010 meeting of the cardiovascular and renal drugs advisory committee. 2010.
66. Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, Nar H, Litzenburger T,. A specific antidote for dabigatran: functional and structural characterization. Blood 2013; 121: 3554-3562.
67. Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, Oldgren J, Themeles E, Wallentin L, Yusuf S,. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009; 157: 805-810, 10 e1-2.
68. Larsen TB, Rasmussen LH, Skjoth F, Due KM, Callreus T, Rosenzweig M, Lip GY,. Efficacy and safety of dabigatran etexilate and warfarin in 'real-world' patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013; 61: 2264-2273.
69. Stangier J,. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47: 285-295. (Pubitemid 351508116)
70. Stollberger C, Finsterer J,. Concerns about storage and application of dabigatran and rivaroxaban. Eur J Clin Pharmacol 2013; 69: 739-740.
71. Brunet A, Hermabessiere S, Benain X,. Monday, 29 August 2011. Eur Heart J 2011; 32: 313-631.
72. Medsafe. Pradaxa: New Zealand datasheet [online]. Available at http://www.medsafe.govt.nz/profs/Datasheet/p/Pradaxacap.pdf (last accessed 28 October 2013).